Dongkook Pharmaceutical Co Equity 2024

Dongkook Pharmaceutical Co Aktienanalyse

What does Dongkook Pharmaceutical Co do?

Dongkook Pharmaceutical Co Ltd is a South Korean company that specializes in the development and manufacturing of pharmaceutical products. It was founded in 1968 by Choon-kyu Kim, who was working in the research department of Pfizer at the time and wanted to start his own company. During the early years, Dongkook focused on the formulation of drugs and medications manufactured by other companies. In the 1980s, Dongkook expanded its business and started developing and manufacturing its own products. A new facility was also built in Bucheon, a suburb of Seoul, during this time. Production focused on prescription medications, particularly cardiovascular drugs and antidiabetic agents. Dongkook became one of the leading companies in South Korea in this area. In the 1990s, Dongkook continued its expansion and began focusing on the Asian market. New markets were tapped into and partnerships with other pharmaceutical companies were established. In 2000, Dongkook went public, providing additional capital. Today, Dongkook is a globally operating company with a wide portfolio of medications and healthcare products. The company is divided into various business segments, including cardiovascular, diabetes, gastrointestinal, and dermatology. Each of these segments encompasses a wide range of products, from prescription drugs to over-the-counter dietary supplements. In the cardiovascular segment, Dongkook offers pharmaceuticals for the treatment of conditions such as heart failure, hypertension, and angina pectoris. The diabetes segment includes medications for the treatment of type 2 diabetes and other metabolic disorders. In the gastrointestinal segment, Dongkook produces medications for the treatment of stomach and intestinal problems, as well as for supporting the digestive system. In dermatology, the company manufactures medications for the treatment of skin diseases and cosmetic products. An important focus of Dongkook is the research and development of new innovative products. The company has its own research and development department, where work is done on new medications and technologies. Through close collaboration with other companies and research institutions around the world, Dongkook has been able to develop numerous products that are distinguished by their high quality and effectiveness. Dongkook is also committed to promoting sustainable and environmentally friendly business practices. The company is dedicated to the use of renewable energies and continuously works on measures to reduce its environmental impact. Additionally, the company is an active member of the community and supports numerous social initiatives, such as donation campaigns for non-profit organizations, educational programs, and environmental conservation projects. In summary, Dongkook Pharmaceutical Co Ltd is a leading global pharmaceutical company known for its innovation, product quality, and sustainable business practices. With a wide portfolio of medications and healthcare products, as well as a strong research and development department, the company is well-positioned for the future and will continue to play an important role in the pharmaceutical industry. Dongkook Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Dongkook Pharmaceutical Co's Equity

Dongkook Pharmaceutical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Dongkook Pharmaceutical Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Dongkook Pharmaceutical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Dongkook Pharmaceutical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Dongkook Pharmaceutical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Dongkook Pharmaceutical Co stock

What is the equity of Dongkook Pharmaceutical Co this year?

Dongkook Pharmaceutical Co has equity of 544.69 B KRW this year.

What was the equity of Dongkook Pharmaceutical Co compared to the previous year?

The equity of Dongkook Pharmaceutical Co has increased/decreased by 8.52% increased compared to the previous year.

What impact does a high equity have on investors of Dongkook Pharmaceutical Co?

A high equity is advantageous for investors of Dongkook Pharmaceutical Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Dongkook Pharmaceutical Co?

A low equity can be a risk for investors of Dongkook Pharmaceutical Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Dongkook Pharmaceutical Co affect the company?

An increase in equity of Dongkook Pharmaceutical Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Dongkook Pharmaceutical Co affect the company?

A reduction in equity of Dongkook Pharmaceutical Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Dongkook Pharmaceutical Co?

Some factors that can affect the equity of Dongkook Pharmaceutical Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Dongkook Pharmaceutical Co so important for investors?

The equity of Dongkook Pharmaceutical Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Dongkook Pharmaceutical Co take to change the equity?

To change equity, Dongkook Pharmaceutical Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Dongkook Pharmaceutical Co pay?

Over the past 12 months, Dongkook Pharmaceutical Co paid a dividend of 180 KRW . This corresponds to a dividend yield of about 1.08 %. For the coming 12 months, Dongkook Pharmaceutical Co is expected to pay a dividend of 196.06 KRW.

What is the dividend yield of Dongkook Pharmaceutical Co?

The current dividend yield of Dongkook Pharmaceutical Co is 1.08 %.

When does Dongkook Pharmaceutical Co pay dividends?

Dongkook Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of Dongkook Pharmaceutical Co?

Dongkook Pharmaceutical Co paid dividends every year for the past 15 years.

What is the dividend of Dongkook Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 196.06 KRW are expected. This corresponds to a dividend yield of 1.18 %.

In which sector is Dongkook Pharmaceutical Co located?

Dongkook Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dongkook Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dongkook Pharmaceutical Co from 4/19/2024 amounting to 180 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did Dongkook Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 4/19/2024.

What was the dividend of Dongkook Pharmaceutical Co in the year 2023?

In the year 2023, Dongkook Pharmaceutical Co distributed 180 KRW as dividends.

In which currency does Dongkook Pharmaceutical Co pay out the dividend?

The dividends of Dongkook Pharmaceutical Co are distributed in KRW.